Abstract
The moss Physcomitrium patens is an advantageous host for the production of biopharmaceutical proteins, particularly due to the ease of glyco-engineering. However, the ability to produce proteins with paucimannosidic (MM) glycans in this species currently depends solely on the nature of the product. MM glycans offer benefits for some therapeutic proteins by facilitating their import into target cells via a presumed mannose receptor. Here, we describe the use of Spodoptera frugiperda enzymes expressed in moss to produce recombinant human lysosomal acid α-glucosidase with mainly MM glycans. We tested the expression of mannosidase type III and a hexosaminidase by varying the promoter strength and protein localization. The parental line produced recombinant α-glucosidase with no detectable MM glycans at all, whereas the weak expression of mannosidase type III targeted to the medial Golgi produced 4% MM glycans. The strong expression of a hexosaminidase targeted to the extracellular space increased the MM glycan content to 43.5%. Unlike previous attempts to express proteins with MM glycans in plants, neither of our introduced modifications interfered with growth or recombinant protein production. Our data confirm that the finely tuned expression and cellular localization of the glycosylation machinery can improve the efficiency of glyco-engineering. We also exploit the assembly of DNA fragments in vivo, which overcomes the limitations of traditional knock-in methods and facilitates the screening of different genetic elements. Our combined methods therefore represent the first straightforward approach allowing the production of recombinant proteins with abundant MM glycans.
Introduction
The moss Physcomitrium (Physcomitrella) patens has unique advantages as a host for the production of biopharmaceuticals, including its amenity for glyco-engineering (). The glycan profile of a therapeutic protein can influence its stability and functionality and is therefore a critical quality attribute in biopharmaceutical manufacturing (). Although glycosylation patterns tend to be more homogenous and stable in moss compared to other platforms, the specific glycan profile depends on the host strain and the product. For example, moss-derived human α-galactosidase A (Repleva AGAL, RPV-001), which has completed phase I clinical trials (), features 57% paucimannosidic (MM) N-linked glycans (). This facilitates the uptake of the drug by target cells, presumably via a yet unknown mannose receptor. In contrast, human lysosomal acid α-glucosidase (Repleva GAA, RPV-002) produced in the same host features mainly N-linked glycans terminating with N-acetylglucosamine (GlcNAc), giving the typical GnGn profile of most proteins expressed in moss (). It would be beneficial to develop engineered moss strains that produce GAA and other proteins with MM glycans to improve their uptake into target cells.
The GnGn profile generally found on moss proteins results from a stereotypical series of reactions in which the core Man8 structure is pared back to Man5 by mannosidase I (ManI), followed by the transfer of a GlcNAc residue by N-acetylglucosaminyltransferase I (GnT-I), the cleavage of two terminal mannose residues by ManII (yielding GnM), and a further transfer of GlcNAc by GnT-II (Supplementary Figure S1). Proteins such as AGAL that naturally display MM glycans in moss are presumed to have structures with a higher affinity for (and/or longer colocalization with) endogenous hexosaminidases, which cleave off terminal GlcNAc residues, potentially in addition to a lower affinity for GnT-II. In contrast, invertebrates such as the armyworm moth Spodoptera frugiperda are known for their dominant MM glycans (), reflecting the presence of a unique ManIII that can cleave terminal mannose residues from Man5 before GnT-I has attached GlcNAc, and is thus able to create MM glycans directly (). GlcNAc residues, which form due to competition for the substrate by GnT-I, can be cleaved by several hexosaminidases. These include the unique fdl gene product, which is found only in insects and specifically cleaves α3-branch GlcNAc residues, as well as broad-spectrum hexosaminidases involved in N-glycan and chitin degradation, which act on both GlcNAc branches ().
In an effort to increase the proportion of MM glycans in moss, we exploited the expression of ManIII to trim oligomannose structures, and hexosaminidase to remove unwanted GlcNAc residues. We found that the expression level and localization of both enzymes was a key determinant of efficiency, and that the fine tuning of expression was necessary to optimize the MM glycan content.
Materials and methods
Plant material and cultivation
All strains used in this study were glyco-engineered descendants of Physcomitrium patens (Hedw.) Mitt. ecotype “Gransden 2004” expressing recombinant human GAA and were cultivated on standard moss medium. Detailed strain description and cultivation conditions can be found in Text S1.
Cell line engineering
Transgenes were synthesized and transferred into our standard expression vector or assembled in vivo. Moss protoplasts were transformed via PEG-based method. Stably transformed moss clones were genotyped by PCR and transgene expression was quantified by real-time RT-PCR (qRT-PCR). Glycan profile was evaluated in 180-mL shake-flask cultures by high-performance liquid chromatography electrospray ionization mass spectrometry (HPLC-ESI-MS) analyses of in-gel digested GAA samples after sodium dodecylsulfate polyacrylamide electrophoresis (SDS-PAGE) separation of secreted proteins. For gel loading, GAA was quantified using an enzyme assay (). Additional details are included in Text S1.
Protein production and glycan analysis
We used 1-L cultures in a stirred-tank bioreactor to represent production conditions as previously described (). Moss culture, GAA enzyme activity assays to determine clonal productivity, SDS-PAGE under reducing conditions, column purification, and the analysis of N-glycans by hydrophilic interaction liquid chromatography (HILIC) were carried out as previously described (). Purified GAA was quantified by size-exclusion high-performance liquid chromatography (SE-HPLC). Briefly, GAA was loaded onto a Yarra SEC-3000 column in a 25 mM sodium phosphate running buffer (pH 6.5) with 100 mM NaCl. For isocratic elution, we applied a flow rate of 0.75 mL/min for 30 min. For quantification, the peak area was analyzed using freely available GAA (Myozyme) as a reference.
Results
We expressed S. frugiperda ManIII in the high-performance GAA-producing moss line Pp_P_GAA-1#007, which has been modified to eliminate the xylT and fucT gene products needed for the synthesis of plant-specific α-1,3-fucose and β-1,2-xylose residues () as well as GnT-I, thus yielding high-mannose N-linked glycans mainly with the structure Man5 (Figure 1A). We expressed ManIII under the control of the strong endogenous moss actin promoter and fused it to the transmembrane domain of endogenous moss ManII for localization to the Golgi, where its substrate is found (Figures 2, S1). Having verified transgene integration and transcription (Supplementary Figures S3, 1B), we screened for MM glycans in GAA recovered from the supernatant of shake-flask cultures following protein separation by SDS-PAGE. However, HPLC-ESI-MS analysis did not detect any MM glycans (Figure 1C).
Figure 1
Figure 2
Overloading the protein secretion machinery can be detrimental (), so we expressed the ManIII under the control of the weaker fucT promoter by using homologous recombination to create a single-copy knock-in strain at the disrupted fucT locus. To provide an expression cassette for the genetic transformation of moss cells, we delivered small PCR fragments, representing the required genetic elements and coding sequences (Supplementary Figure S2), into the cells and used the in vivo assembly capabilities of moss for stable genetic transformation. With this approach, we achieved a knock-in success rate of 15.8% (Supplementary Figure S4). Transcript analysis confirmed that the SfManIII transgene was expressed at a lower level when driven by the fucT promoter, verifying the knock-in strategy (Figure 1B). HPLC-ESI-MS analysis revealed the presence of a small quantity of MM glycans in clones T9#009 (4%) and T9#296 (0.1%), relative to the sum of all identified and glycosylated GAA peptides (Figure 1C).
We previously generated Repleva GAA with MM glycans by using the bacterial hexosaminidase β-N-acetylglucosaminidase S from Streptomyces plicatus (SpHexo) for the modification of purified GAA in vitro (). However, when we expressed SpHexo in the high-performance GAA-producing moss line Pp_P_GAA-1#001, which has been modified to eliminate the xylT and fucT genes () but retains GnT-I and therefore synthesizes mainly GnGn glycans (Figure 1D), we were unable to detect SpHexo transcription in any transgenic lines after several attempts to achieve stable transgene integration (data not shown). This suggests the product is toxic (Text S3). The addition of a signal peptide targeting the protein for secretion to avoid interference with Golgi-resident host proteins did not resolve this issue. We therefore expressed the broad-spectrum S. frugiperda hexosaminidase (SfHexo) in the same parent strain, this time fusing the protein to the transmembrane domain of FucT and following the same expression strategy as described above for SfManIII. We used the strong actin promoter for SfHexo and obtained clones with varying expression levels during screening (Figures 1E, S5), but again detected no MM glycans by HPLC-ESI-MS (Figure 1F). Localization within the late Golgi may prevent enzyme processing for activation or limit the colocalization of SfHexo with its substrate, so we expressed a soluble SfHexo without a transmembrane domain instead. This finally yielded two clones with 34.1% (T7#006) and 15.2% (T7#267) MM glycans, respectively (Figure 1F).
To quantify the portion of MM glycans in a production setting, we repeated the cultivation in a stirred-tank bioreactor using the best-performing strain (T7#006) along with the parent strain. During a 14-day cultivation experiment, both strains showed comparable morphology, growth and GAA production (Figures 3A-C). We extensively purified the GAA (Figure 4A, Text S2) to enable product-specific quantification of the cleaved glycans by HILIC, confirming that the GAA features up to 43.5% MM glycans (including methylated derivatives) and the GnGn content fell from 61.5% in the parental strain to 15.2% in the engineered line (Figures 4B, C).
Figure 3
Figure 4
Discussion
Glycosylated therapeutic proteins usually feature complex glycans terminated with GlcNAc or sialic acid residues (; ). However, paucimannosidic (MM) N-glycans facilitate the uptake of proteins via mannose receptors, as shown for AGAL () and potentially for other lysosomal storage disease-associated proteins such as GAA (). Recombinant proteins with MM glycans can be produced by cleaving off GlcNAc residues in vitro using a bacterial hexosaminidase, but this adds a process-related impurity that must be removed in a subsequent step, increasing costs (). The direct formation of MM glycans in the production host would be more elegant, as achieved when using the baculovirus expression system in Sf9 insect cells due to their prominent hexosaminidase activity (; ). Plant expression hosts typically produce complex-type N-linked glycans terminated with GlcNAc residues (; ; ; ), although MM is found more rarely (; ). Strategies that favor MM glycans include directing recombinant proteins to the vacuole, which contains hexosaminidases (), or using the Arabidopsis alg3 mutant, which inhibits glycan maturation in the Golgi, although the latter induces ER stress and reduces overall yields (). We decided to equip our moss platform with the enzymes needed to produce MM glycans to expand our glyco-engineering toolbox and benefit from our previous achievements, i.e. efficient secretion of a recombinant protein lacking plant-specific xylose and fucose residues (). The hereby tested in vivo assembly approach offers a straightforward approach to facilitate cell line engineering (; Text S3).
SfManIII was suitable for the production of recombinant GAA with MM glycans but it was important to tune the expression levels carefully to avoid overloading the secretion machinery (). We fused SfManIII to the transmembrane domain of moss ManII to ensure localization in early Golgi vessels () but detected only traces of the product. Glycosyltransferase activity is finely tuned by enzyme localization and multimerization (). Given that SfManIII is a type II α-mannosidase that forms multimers (; ; ), overcrowding may reduce its activity by constraining interactions involving the transmembrane and lumenal domain by changing membrane curvature, reducing the lateral diffusion rate, and compressing the distance between subunits (; ).
We achieved the highest proportion of MM glycans by expressing SfHexo under the control of a strong promoter and secreting it to the extracellular space. When we targeted the late Golgi by fusing the lumenal domain of SfHexo to the transmembrane domain of FucT (), we observed no activity at high or low expression levels. Native SfHexo is known to localize in secretory vesicles and outside the cell (; ). We therefore cannot exclude the possibility that SfHexo exists as a pro-enzyme that must be processed as it moves through the secretory pathway to gain full activity (). This is supported by our observation that only the secreted version of the enzyme was active. Another reason could be a prolonged co-localization of SfHexo with its secreted substrate GAA or a combination of both.
In conclusion, our results highlight the importance of appropriate expression levels and protein localization for components of the glycosylation machinery when optimizing the glyco-engineering of recombinant proteins (). Further engineering attempts, by testing other enzymes, different subcellular compartments and expression levels, may determine whether the MM content can be increased even more or if there is a maximum that moss can tolerate. Each attempt at glyco-engineering has the potential to alter host cell proteins and may negatively affect host physiology. However, the moss strain reported here shows no adverse changes in morphology, growth, or productivity, in agreement with many previous glyco-engineering experiments (; ; ; ; ). This confirms the amenability of moss for glyco-engineering, as also reported in other plants such as tobacco ().
Statements
Data availability statement
The datasets presented in this study can be found in online repositories. The names of the repository/repositories and accession number(s) can be found in the article/Supplementary Material.
Author contributions
JJ: Investigation, Writing – review & editing. BF: Supervision, Writing – review & editing. JK: Supervision, Writing – review & editing. SB: Supervision, Writing – review & editing. PD-S: Conceptualization, Writing – review & editing. AS: Writing – review & editing, Conceptualization. CS: Writing – original draft, Writing – review & editing, Project administration, Conceptualization, Supervision.
Funding
The author(s) declare that financial support was received for the research and/or publication of this article. The work was funded by Eleva GmbH.
Acknowledgments
We acknowledge Prof. Friedrich Altmann and Dr. Clemens Grünwald-Gruber for HILIC and LC-ESI-MS analysis. We thank team Eleva for excellent technical assistance. We are grateful to Dr. Richard M. Twyman for language editing.
Conflict of interest
The authors are employed by Eleva GmbH. Data from this study have been included in patent application EP24186910.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Supplementary material
The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fpls.2025.1605548/full#supplementary-material
References
1
AumillerJ. J.HollisterJ. R.JarvisD. L. (2006). Molecular cloning and functional characterization of β-N-acetylglucosaminidase genes from Sf9 cells. Protein Expr. Purif.47, 571–590. doi: 10.1016/j.pep.2005.11.026
2
BohlenderL. L.ParsonsJ.HoernsteinS. N. W.RempferC.Ruiz-MolinaN.LorenzT.et al. (2020). Stable protein sialylation in Physcomitrella. Front. Plant Sci.11, 610032. doi: 10.3389/fpls.2020.610032
3
BontenE. J.WangD.ToyJ. N.MannL.MignardotA.YogalingamG.et al. (2004). Targeting macrophages with baculovirus-produced lysosomal enzymes: implications for enzyme replacement therapy of the glycoprotein storage disorder galactosialidosis. FASEB J.18, 971–973. doi: 10.1096/fj.03-0941fje
4
DeckerE. L.ReskiR. (2020). Mosses in biotechnology. Curr. Opin. Biotechnol.61, 21–27. doi: 10.1016/j.copbio.2019.09.021
5
El-BattariA.ProrokM.AngataK.MathieuS.ZerfaouiM.OngE.et al. (2003). Different glycosyltransferases are differentially processed for secretion, dimerization, and autoglycosylation. Glycobiology13, 941–953. doi: 10.1093/glycob/cwg117
6
Fitchette-LainéA.-C.GomordV.ChekkafiA.FayeL. (1994). Distribution of xylosylation and fucosylation in the plant Golgi apparatus. Plant J.5, 673–682. doi: 10.1111/j.1365-313X.1994.00673.x
7
GeislerC.AumillerJ. J.JarvisD. L. (2008). A fused lobes gene encodes the processing β-N-Acetylglucosaminidase in Sf9 cells. J. Biol. Chem.283, 11330–11339. doi: 10.1074/jbc.M710279200
8
HananiaU.ArielT.TekoahY.FuxL.ShevaM.GubbayY.et al. (2017). Establishment of a tobacco BY2 cell line devoid of plant-specific xylose and fucose as a platform for the production of biotherapeutic proteins. Plant Biotechnol. J.15, 1120–1129. doi: 10.1111/pbi.2017.15.issue-9
9
HennermannJ. B.Arash-KapsL.FeketeG.SchaafA.BuschA.FrischmuthT. (2019). Pharmacokinetics, pharmacodynamics, and safety of moss-aGalactosidase A in patients with Fabry disease. J. Inher. Metab. Dis.42, 527–533. doi: 10.1002/jimd.2019.42.issue-3
10
HintzeS.LimmerS.Dabrowska-SchleppP.BergB.KrieghoffN.BuschA.et al. (2020). Moss-derived human recombinant GAA provides an optimized enzyme uptake in differentiated human muscle cells of Pompe disease. Int. J. Mol. Sci.21, 2642. doi: 10.3390/ijms21072642
11
KawarZ.KaravegK.MoremenK. W.JarvisD. L. (2001). Insect cells encode a class II α-mannosidase with unique properties. J. Biol. Chem.276, 16335–16340. doi: 10.1074/jbc.M100119200
12
KimY. K.KimK. R.KangD. G.JangS. Y.KimY. H.ChaH. J. (2009). Suppression of β-N-acetylglucosaminidase in the N-glycosylation pathway for complex glycoprotein formation in Drosophila S2 cells. Glycobiology19, 301–308. doi: 10.1093/glycob/cwn138
13
KingB. C.VavitsasK.IkramN. K. B. K.SchrøderJ.ScharffL. B.HambergerB.et al. (2016). In vivo assembly of DNA fragments in the moss, Physcomitrella patens. Sci. Rep.6, 25030. doi: 10.1038/srep25030
14
KitturF. S.HungC.-Y.ZhuC.ShajahanA.AzadiP.ThomasM. D.et al. (2020). Glycoengineering tobacco plants to stably express recombinant human erythropoietin with different N-glycan profiles. Int. J. Biol. Macromol.157, 158–169. doi: 10.1016/j.ijbiomac.2020.04.199
15
KoprivovaA.StemmerC.AltmannF.HoffmannA.KoprivaS.GorrG.et al. (2004). Targeted knockouts of Physcomitrella lacking plant-specific immunogenic N-glycans. Plant Biotechnol. J.2, 517–523. doi: 10.1111/j.1467-7652.2004.00100.x
16
KuokkanenE.SmithW.MäkinenM.TuominenH.PuhkaM.JokitaloE.et al. (2007). Characterization and subcellular localization of human neutral class II α-mannosidase cytosolic enzymes/free oligosaccharides/glycosidehydrolase family 38/M2C1/N-glycosylation. Glycobiology17, 1084–1093. doi: 10.1093/glycob/cwm083
17
LöweM.KalachevaM.BoersmaA. J.KedrovA. (2020). The more the merrier: effects of macromolecular crowding on the structure and dynamics of biological membranes. FEBS J.287, 5039–5067. doi: 10.1111/febs.v287.23
18
NemčovičováI.ŠestákS.RendićD.PlškováM.MuchaJ.WilsonI. B. H. (2013). Characterisation of class I and II α-mannosidases from Drosophila melanogaster. Glycoconj. J.30, 899–909. doi: 10.1007/s10719-013-9495-5
19
ParsonsJ.AltmannF.ArrenbergC. K.KoprivovaA.BeikeA. K.StemmerC.et al. (2012). Moss-based production of asialo-erythropoietin devoid of Lewis A and other plant-typical carbohydrate determinants. Plant Biotechnol. J.10, 851–861. doi: 10.1111/j.1467-7652.2012.00704.x
20
PlattF. M.d’AzzoA.DavidsonB. L.NeufeldE. F.TifftC. J. (2018). Lysosomal storage diseases. Nat. Rev. Dis. Primers4, 1–25. doi: 10.1038/s41572-018-0025-4
21
SariyatunR.FlorenceKajiuraH.OhashiT.MisakiR.FujiyamaK. (2021). Production of human acid-alpha glucosidase with a paucimannose structure by glycoengineered Arabidopsis cell culture. Front. Plant Sci.12, 703020. doi: 10.3389/fpls.2021.703020
22
SchmittgenT. D.LivakK. J. (2008). Analyzing real-time PCR data by the comparative CT method. Nat. Prot.3, 1101–1108. doi: 10.1038/nprot.2008.73
23
ShaaltielY.BartfeldD.HashmueliS.BaumG.Brill-AlmonE.GaliliG.et al. (2007). Production of glucocerebrosidase with terminal mannose glycans for enzyme replacement therapy of Gaucher’s disease using a plant cell system. Plant Biotechnol. J.5, 579–590. doi: 10.1111/j.1467-7652.2007.00263.x
24
ShenJ.-S.BuschA.DayT. S.MengX.-L.YuC. I.Dabrowska-SchleppP.et al. (2016). Mannose receptor-mediated delivery of moss-made α-galactosidase A efficiently corrects enzyme deficiency in Fabry mice. J. Inher. Metab. Dis.39, 293–303. doi: 10.1007/s10545-015-9886-9
25
ShiX.JarvisD. L. (2007). Protein N-glycosylation in the baculovirus–insect cell system. Curr. Drug Targets8, 1116–1125. doi: 10.2174/138945007782151360
26
ShinY.CastilhoA.DickerM.SádioF.VavraU.Grünwald-GruberC.et al. (2017). Reduced paucimannosidic N-glycan formation by suppression of a specific β-hexosaminidase from Nicotiana benthamiana. Plant Biotechnol. J.15, 197–206. doi: 10.1111/pbi.2017.15.issue-2
27
StrasserR. (2023). Plant glycoengineering for designing next-generation vaccines and therapeutic proteins. Biotechnol. Adv.67, 108197. doi: 10.1016/j.biotechadv.2023.108197
28
StrasserR.SchobererJ.JinC.GlösslJ.MachL.SteinkellnerH. (2006). Molecular cloning and characterization of Arabidopsis thaliana Golgi α-mannosidase II, a key enzyme in the formation of complex N-glycans in plants. Plant J.45, 789–803. doi: 10.1111/j.1365-313X.2005.02648.x
29
TekoahY.ShulmanA.KizhnerT.RuderferI.FuxL.NatafY.et al. (2015). Large-scale production of pharmaceutical proteins in plant cell culture—the Protalix experience. Plant Biotechnol. J.13, 1199–1208. doi: 10.1111/pbi.2015.13.issue-8
30
TomiyaN.NarangS.ParkJ.Abdul-RahmanB.ChoiO.SinghS.et al. (2006). Purification, characterization, and cloning of a Spodoptera frugiperda Sf9 β-N-acetylhexosaminidase that hydrolyzes terminal N-acetylglucosamine on the N-glycan core. J. Biol. Chem.281, 19545–19560. doi: 10.1074/jbc.M603312200
31
TorresM.HussainH.DicksonA. J. (2022). The secretory pathway – the key for unlocking the potential of Chinese hamster ovary cell factories for manufacturing therapeutic proteins. Crit. Rev. Biotechnol.43, 628–645. doi: 10.1080/07388551.2022.2047004
32
TschongovT.KonwarS.BuschA.SievertC.HartmannA.NorisM.et al. (2024). Moss-produced human complement factor H with modified glycans has an extended half-life and improved biological activity. Front. Immunol.15, 1383123. doi: 10.3389/fimmu.2024.1383123
33
WelchL. G.MunroS. (2019). A tale of short tails, through thick and thin: investigating the sorting mechanisms of Golgi enzymes. FEBS Lett.593, 2452–2465. doi: 10.1002/1873-3468.13553
Summary
Keywords
paucimannosidic glycans, glyco-engineering, lysosomal acid α-glucosidase, Physcomitrium patens, hexosaminidase
Citation
Jonner J, Fode B, Koch J, Boller S, Dabrowska-Schlepp P, Schaaf A and Sievert C (2025) Engineering the moss Physcomitrium patens to produce proteins with paucimannosidic glycans. Front. Plant Sci. 16:1605548. doi: 10.3389/fpls.2025.1605548
Received
03 April 2025
Accepted
05 June 2025
Published
11 July 2025
Volume
16 - 2025
Edited by
Kevin Yueju Wang, University of Pikeville, United States
Reviewed by
Lilya Kopertekh, Julius Kühn-Institut, Germany
Md. Rezaul Islam Khan, Michigan Technological University, United States
Updates
Copyright
© 2025 Jonner, Fode, Koch, Boller, Dabrowska-Schlepp, Schaaf and Sievert.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Christian Sievert, csievert@elevabiologics.com
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.